益生菌对溃疡性结肠炎促炎细胞因子和 NF-κB 激活的影响。
Effect of probiotics on pro-inflammatory cytokines and NF-kappaB activation in ulcerative colitis.
机构信息
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta 8130, Egypt.
出版信息
World J Gastroenterol. 2010 Sep 7;16(33):4145-51. doi: 10.3748/wjg.v16.i33.4145.
AIM
To demonstrate the therapeutic effect of probiotics in patients with ulcerative colitis (UC), and their effect on inflammatory mediators and nuclear factor (NF)-kappaB activation in these patients.
METHODS
Thirty patients with mild to moderate UC were randomly classified into two groups: sulfasalazine group, who received sulfasalazine 2400 mg/d; and probiotic group, who received sulfasalazine 2400 mg/d with probiotic. The patients were investigated before and after 8 wk of treatment with probiotic (Lactobacillus delbruekii and Lactobacillus fermentum). Colonic activity of myeloperoxidase (MPO) was assayed with UV spectrophotometry, the colonic content of interleukin (IL)-6 was determined by enzyme-linked immunosorbent assay (ELISA), fecal calprotectin was determined by ELISA, and expression of NF-kappaB p65 and tumor necrosis factor (TNF)-alpha proteins in colonic tissue was identified by immunohistochemistry and reverse transcription polymerase chain reaction, respectively.
RESULTS
At the start of the study, colonic mucosal injury and inflammation were demonstrated in UC patients by hematoxylin and eosin staining, and an increase in colonic MPO activity, fecal calprotectin, and expression of colonic TNF-alpha and NF-kappaB p65 proteins. The use of probiotic for 8 wk significantly ameliorated the inflammation by decreasing the colonic concentration of IL-6, expression of TNF-alpha and NF-kappaB p65, leukocyte recruitment, as demonstrated by a decrease in colonic MPO activity, and the level of fecal calprotectin compared to sulfasalazine group and the control group (P < 0.05).
CONCLUSION
Oral supplementation with probiotics could be helpful in maintaining remission and preventing relapse of UC.
目的
展示益生菌对溃疡性结肠炎（UC）患者的治疗效果，以及它们对这些患者炎症介质和核因子（NF）-κB 激活的影响。
方法
将 30 例轻中度 UC 患者随机分为两组：柳氮磺胺吡啶组，给予柳氮磺胺吡啶 2400mg/d；益生菌组，给予柳氮磺胺吡啶 2400mg/d 加益生菌。在给予益生菌 8 周前后，用紫外分光光度法检测髓过氧化物酶（MPO）在结肠中的活性，用酶联免疫吸附试验（ELISA）检测白细胞介素（IL）-6 的含量，用 ELISA 检测粪便钙卫蛋白，用免疫组化和逆转录聚合酶链反应分别检测 NF-κB p65 和肿瘤坏死因子（TNF）-α 蛋白在结肠组织中的表达。
结果
在研究开始时，通过苏木精和伊红染色显示 UC 患者结肠黏膜损伤和炎症，并通过结肠 MPO 活性、粪便钙卫蛋白和结肠 TNF-α和 NF-κB p65 蛋白的表达增加来证明。用益生菌治疗 8 周后，通过降低结肠中 IL-6 的浓度、TNF-α和 NF-κB p65 的表达、白细胞募集，从而显著改善炎症，如结肠 MPO 活性降低，粪便钙卫蛋白水平降低，与柳氮磺胺吡啶组和对照组相比（P<0.05）。
结论
口服补充益生菌有助于维持 UC 的缓解和预防复发。
Zotero 插件